Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer

Valerie M. Jansen, Neil E. Bhola, Joshua A. Bauer, Luigi Formisano, Kyung Min Lee, Katherine E. Hutchinson, Agnieszka K. Witkiewicz, Preston D. Moore, Mónica Valéria Estrada, Violeta Sánchez, Paula G. Ericsson, Melinda E. Sanders, Paula R. Pohlmann, Michael J. Pishvaian, David A. Riddle, Teresa C. Dugger, Wenyi Wei, Erik S. Knudsen, Carlos L. Arteaga

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule inhibitors in breast cancer arises through mechanisms that are yet uncharacterized. In this study, we used a kinome-wide siRNA screen to identify kinases that, when downregulated, yield sensitivity to the CDK4/6 inhibitor ribociclib. In this manner, we identified 3-phosphoinositidedependent protein kinase 1 (PDK1) as a key modifier of ribociclib sensitivity in estrogen receptor-positive MCF-7 breast cancer cells. Pharmacologic inhibition of PDK1 with GSK2334470 in combination with ribociclib or palbociclib, another CDK4/6 inhibitor, synergistically inhibited proliferation and increased apoptosis in a panel of ER-positive breast cancer cell lines. Ribociclib-resistant breast cancer cells selected by chronic drug exposure displayed a relative increase in the levels of PDK1 and activation of the AKT pathway. Analysis of these cells revealed that CDK4/6 inhibition failed to induce cell-cycle arrest or senescence. Mechanistic investigations showed that resistant cells coordinately upregulated expression of cyclins A, E, and D1, activated phospho-CDK2, and phospho-S477/T479 AKT. Treatment with GSK2334470 or the CDK2 inhibitor dinaciclib was sufficient to reverse these events and to restore the sensitivity of ribociclib-resistant cells to CDK4/6 inhibitors. Ribociclib, in combination with GSK2334470 or the PI3Kα inhibitor alpelisib, decreased xenograft tumor growth more potently than each drug alone. Taken together, our results highlight a role for the PI3K-PDK1 signaling pathway in mediating acquired resistance to CDK4/6 inhibitors.

Original languageEnglish (US)
Pages (from-to)2488-2499
Number of pages12
JournalCancer Research
Volume77
Issue number9
DOIs
StatePublished - May 1 2017

Fingerprint

Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 4
RNA Interference
Protein Kinases
Breast Neoplasms
Phosphatidylinositol 3-Kinases
Cyclin A
Cyclin E
Cell Aging
Cyclin D1
Cell Cycle Checkpoints
Heterografts
Estrogen Receptors
Pharmaceutical Preparations
Small Interfering RNA
ribociclib
Phosphotransferases
Down-Regulation
Apoptosis
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. / Jansen, Valerie M.; Bhola, Neil E.; Bauer, Joshua A.; Formisano, Luigi; Lee, Kyung Min; Hutchinson, Katherine E.; Witkiewicz, Agnieszka K.; Moore, Preston D.; Estrada, Mónica Valéria; Sánchez, Violeta; Ericsson, Paula G.; Sanders, Melinda E.; Pohlmann, Paula R.; Pishvaian, Michael J.; Riddle, David A.; Dugger, Teresa C.; Wei, Wenyi; Knudsen, Erik S.; Arteaga, Carlos L.

In: Cancer Research, Vol. 77, No. 9, 01.05.2017, p. 2488-2499.

Research output: Contribution to journalArticle

Jansen, VM, Bhola, NE, Bauer, JA, Formisano, L, Lee, KM, Hutchinson, KE, Witkiewicz, AK, Moore, PD, Estrada, MV, Sánchez, V, Ericsson, PG, Sanders, ME, Pohlmann, PR, Pishvaian, MJ, Riddle, DA, Dugger, TC, Wei, W, Knudsen, ES & Arteaga, CL 2017, 'Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer', Cancer Research, vol. 77, no. 9, pp. 2488-2499. https://doi.org/10.1158/0008-5472.CAN-16-2653
Jansen, Valerie M. ; Bhola, Neil E. ; Bauer, Joshua A. ; Formisano, Luigi ; Lee, Kyung Min ; Hutchinson, Katherine E. ; Witkiewicz, Agnieszka K. ; Moore, Preston D. ; Estrada, Mónica Valéria ; Sánchez, Violeta ; Ericsson, Paula G. ; Sanders, Melinda E. ; Pohlmann, Paula R. ; Pishvaian, Michael J. ; Riddle, David A. ; Dugger, Teresa C. ; Wei, Wenyi ; Knudsen, Erik S. ; Arteaga, Carlos L. / Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. In: Cancer Research. 2017 ; Vol. 77, No. 9. pp. 2488-2499.
@article{cd8598a7ef084d28be30fb65d97bcc73,
title = "Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer",
abstract = "Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule inhibitors in breast cancer arises through mechanisms that are yet uncharacterized. In this study, we used a kinome-wide siRNA screen to identify kinases that, when downregulated, yield sensitivity to the CDK4/6 inhibitor ribociclib. In this manner, we identified 3-phosphoinositidedependent protein kinase 1 (PDK1) as a key modifier of ribociclib sensitivity in estrogen receptor-positive MCF-7 breast cancer cells. Pharmacologic inhibition of PDK1 with GSK2334470 in combination with ribociclib or palbociclib, another CDK4/6 inhibitor, synergistically inhibited proliferation and increased apoptosis in a panel of ER-positive breast cancer cell lines. Ribociclib-resistant breast cancer cells selected by chronic drug exposure displayed a relative increase in the levels of PDK1 and activation of the AKT pathway. Analysis of these cells revealed that CDK4/6 inhibition failed to induce cell-cycle arrest or senescence. Mechanistic investigations showed that resistant cells coordinately upregulated expression of cyclins A, E, and D1, activated phospho-CDK2, and phospho-S477/T479 AKT. Treatment with GSK2334470 or the CDK2 inhibitor dinaciclib was sufficient to reverse these events and to restore the sensitivity of ribociclib-resistant cells to CDK4/6 inhibitors. Ribociclib, in combination with GSK2334470 or the PI3Kα inhibitor alpelisib, decreased xenograft tumor growth more potently than each drug alone. Taken together, our results highlight a role for the PI3K-PDK1 signaling pathway in mediating acquired resistance to CDK4/6 inhibitors.",
author = "Jansen, {Valerie M.} and Bhola, {Neil E.} and Bauer, {Joshua A.} and Luigi Formisano and Lee, {Kyung Min} and Hutchinson, {Katherine E.} and Witkiewicz, {Agnieszka K.} and Moore, {Preston D.} and Estrada, {M{\'o}nica Val{\'e}ria} and Violeta S{\'a}nchez and Ericsson, {Paula G.} and Sanders, {Melinda E.} and Pohlmann, {Paula R.} and Pishvaian, {Michael J.} and Riddle, {David A.} and Dugger, {Teresa C.} and Wenyi Wei and Knudsen, {Erik S.} and Arteaga, {Carlos L.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-16-2653",
language = "English (US)",
volume = "77",
pages = "2488--2499",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer

AU - Jansen, Valerie M.

AU - Bhola, Neil E.

AU - Bauer, Joshua A.

AU - Formisano, Luigi

AU - Lee, Kyung Min

AU - Hutchinson, Katherine E.

AU - Witkiewicz, Agnieszka K.

AU - Moore, Preston D.

AU - Estrada, Mónica Valéria

AU - Sánchez, Violeta

AU - Ericsson, Paula G.

AU - Sanders, Melinda E.

AU - Pohlmann, Paula R.

AU - Pishvaian, Michael J.

AU - Riddle, David A.

AU - Dugger, Teresa C.

AU - Wei, Wenyi

AU - Knudsen, Erik S.

AU - Arteaga, Carlos L.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule inhibitors in breast cancer arises through mechanisms that are yet uncharacterized. In this study, we used a kinome-wide siRNA screen to identify kinases that, when downregulated, yield sensitivity to the CDK4/6 inhibitor ribociclib. In this manner, we identified 3-phosphoinositidedependent protein kinase 1 (PDK1) as a key modifier of ribociclib sensitivity in estrogen receptor-positive MCF-7 breast cancer cells. Pharmacologic inhibition of PDK1 with GSK2334470 in combination with ribociclib or palbociclib, another CDK4/6 inhibitor, synergistically inhibited proliferation and increased apoptosis in a panel of ER-positive breast cancer cell lines. Ribociclib-resistant breast cancer cells selected by chronic drug exposure displayed a relative increase in the levels of PDK1 and activation of the AKT pathway. Analysis of these cells revealed that CDK4/6 inhibition failed to induce cell-cycle arrest or senescence. Mechanistic investigations showed that resistant cells coordinately upregulated expression of cyclins A, E, and D1, activated phospho-CDK2, and phospho-S477/T479 AKT. Treatment with GSK2334470 or the CDK2 inhibitor dinaciclib was sufficient to reverse these events and to restore the sensitivity of ribociclib-resistant cells to CDK4/6 inhibitors. Ribociclib, in combination with GSK2334470 or the PI3Kα inhibitor alpelisib, decreased xenograft tumor growth more potently than each drug alone. Taken together, our results highlight a role for the PI3K-PDK1 signaling pathway in mediating acquired resistance to CDK4/6 inhibitors.

AB - Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule inhibitors in breast cancer arises through mechanisms that are yet uncharacterized. In this study, we used a kinome-wide siRNA screen to identify kinases that, when downregulated, yield sensitivity to the CDK4/6 inhibitor ribociclib. In this manner, we identified 3-phosphoinositidedependent protein kinase 1 (PDK1) as a key modifier of ribociclib sensitivity in estrogen receptor-positive MCF-7 breast cancer cells. Pharmacologic inhibition of PDK1 with GSK2334470 in combination with ribociclib or palbociclib, another CDK4/6 inhibitor, synergistically inhibited proliferation and increased apoptosis in a panel of ER-positive breast cancer cell lines. Ribociclib-resistant breast cancer cells selected by chronic drug exposure displayed a relative increase in the levels of PDK1 and activation of the AKT pathway. Analysis of these cells revealed that CDK4/6 inhibition failed to induce cell-cycle arrest or senescence. Mechanistic investigations showed that resistant cells coordinately upregulated expression of cyclins A, E, and D1, activated phospho-CDK2, and phospho-S477/T479 AKT. Treatment with GSK2334470 or the CDK2 inhibitor dinaciclib was sufficient to reverse these events and to restore the sensitivity of ribociclib-resistant cells to CDK4/6 inhibitors. Ribociclib, in combination with GSK2334470 or the PI3Kα inhibitor alpelisib, decreased xenograft tumor growth more potently than each drug alone. Taken together, our results highlight a role for the PI3K-PDK1 signaling pathway in mediating acquired resistance to CDK4/6 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85018607476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018607476&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-2653

DO - 10.1158/0008-5472.CAN-16-2653

M3 - Article

C2 - 28249908

AN - SCOPUS:85018607476

VL - 77

SP - 2488

EP - 2499

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 9

ER -